206 related articles for article (PubMed ID: 17121873)
1. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
[TBL] [Abstract][Full Text] [Related]
2. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55.
Durrant LG; Maxwell-Armstrong C; Buckley D; Amin S; Robins RA; Carmichael J; Scholefield JH
Clin Cancer Res; 2000 Feb; 6(2):422-30. PubMed ID: 10690519
[TBL] [Abstract][Full Text] [Related]
3. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
Ullenhag GJ; Spendlove I; Watson NF; Kallmeyer C; Pritchard-Jones K; Durrant LG
Clin Immunol; 2008 Aug; 128(2):148-54. PubMed ID: 18508409
[TBL] [Abstract][Full Text] [Related]
4. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer.
Maxwell-Armstrong CA; Durrant LG; Buckley TJ; Scholefield JH; Robins RA; Fielding K; Monson JR; Guillou P; Calvert H; Carmichael J; Hardcastle JD
Br J Cancer; 2001 Jun; 84(11):1443-6. PubMed ID: 11384090
[TBL] [Abstract][Full Text] [Related]
5. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody.
Robins RA; Denton GW; Hardcastle JD; Austin EB; Baldwin RW; Durrant LG
Cancer Res; 1991 Oct; 51(19):5425-9. PubMed ID: 1913661
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
[TBL] [Abstract][Full Text] [Related]
7. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses.
Buckley DT; Robins AR; Durrant LG
Hum Antibodies Hybridomas; 1995; 6(2):68-72. PubMed ID: 7492753
[TBL] [Abstract][Full Text] [Related]
8. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
Spendlove L; Li L; Potter V; Christiansen D; Loveland BE; Durrant LG
Eur J Immunol; 2000 Oct; 30(10):2944-53. PubMed ID: 11069077
[TBL] [Abstract][Full Text] [Related]
9. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ
Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514
[TBL] [Abstract][Full Text] [Related]
10. A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer.
Samonigg H; Wilders-Truschnig M; Kuss I; Plot R; Stöger H; Schmid M; Bauernhofer T; Tiran A; Pieber T; Havelec L; Loibner H
J Immunother; 1999 Nov; 22(6):481-8. PubMed ID: 10570746
[TBL] [Abstract][Full Text] [Related]
11. A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carcinoma patients.
Li G; Xie L; Zhou G; Fu H; Zhou J; Sun Q
Chin Med J (Engl); 2002 Apr; 115(4):567-70. PubMed ID: 12133300
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
[TBL] [Abstract][Full Text] [Related]
13. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
[TBL] [Abstract][Full Text] [Related]
14. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
15. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
[TBL] [Abstract][Full Text] [Related]
17. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody.
Chatterjee SK; Tripathi PK; Chakraborty M; Yannelli J; Wang H; Foon KA; Maier CC; Blalock JE; Bhattacharya-Chatterjee M
Cancer Res; 1998 Mar; 58(6):1217-24. PubMed ID: 9515808
[TBL] [Abstract][Full Text] [Related]
18. Vaccine-induced apoptosis: a novel clinical trial end point?
Amin S; Robins RA; Maxwell-Armstrong CA; Scholefield JH; Durrant LG
Cancer Res; 2000 Jun; 60(12):3132-6. PubMed ID: 10866299
[TBL] [Abstract][Full Text] [Related]
19. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.
Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Clin Cancer Res; 2007 Mar; 13(5):1503-10. PubMed ID: 17332295
[TBL] [Abstract][Full Text] [Related]
20. Current concepts in immunotherapy for the treatment of colorectal cancer.
Indar A; Maxwell-Armstrong CA; Durrant LG; Carmichael J; Scholefield JH
J R Coll Surg Edinb; 2002 Apr; 47(2):458-74. PubMed ID: 12018689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
